Keytruda

Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer
Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer
BioSpace
Merck
Keytruda
gastric cancer
Flag link:
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Fierce Pharma
Merck
AstraZeneca
biliary tract cancer
Keytruda
Imfinzi
Flag link:
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
Flag link:
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
Flag link:
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
Fierce Pharma
Merck
GSK
Keytruda
Jemperli
ESMO
nonsquamous non-small cell lung cancer
Flag link:
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Flag link:
Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval
Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval
BioSpace
Merck
Keytruda
non-small cell lung cancer
Flag link:
Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
Flag link:
Merck eyes new bladder cancer space with positive Keytruda trial in muscle-invasive disease
Merck eyes new bladder cancer space with positive Keytruda trial in muscle-invasive disease
Fierce Pharma
Merck
Keytruda
bladder cancer
muscle-invasive urothelial carcinoma
Flag link:
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
Flag link:
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Yahoo/Zacks.com
Merck
Keytruda
FDA
cervical cancer
priority review
Flag link:
1ST Biotherapeutics and Merck to assess cancer combination treatment
1ST Biotherapeutics and Merck to assess cancer combination treatment
Clinical Trials Arena
Merck
1st Biotherapeutics
Keytruda
solid tumors
clinical trials
Flag link:
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
head and neck cancer
Flag link:
Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown
Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown
Medical Marketing and Media
Merck
Keytruda
Roche
branding
Flag link:
Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown
Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown
Fierce Pharma
Merck
Roche
pharma sales
Keytruda
Flag link:
Gilead antibody drug shows signs of potential in early lung cancer
Gilead antibody drug shows signs of potential in early lung cancer
BioPharma Dive
Gilead Sciences
Trodelvy
Merck
Keytruda
lung cancer
Flag link:
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Clinical Trials Arena
Eli Lilly
clinical trials
Retevmo
non-small cell lung cancer
Keytruda
Flag link:
Moderna plots lung cancer trial for Merck-partnered vax, piggybacking on Keytruda's recent win
Moderna plots lung cancer trial for Merck-partnered vax, piggybacking on Keytruda's recent win
Fierce Biotech
Moderna Therapeutics
lung cancer
Merck
vaccines
Keytruda
Flag link:
Merck's Keytruda meets main goal in late-stage breast cancer study
Merck's Keytruda meets main goal in late-stage breast cancer study
Reuters
Merck
Keytruda
clinical trials
breast cancer
Flag link:

Pages